Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
- PMID: 37752114
- PMCID: PMC10522597
- DOI: 10.1038/s41408-023-00923-6
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
Erratum for
-
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.Blood Cancer J. 2023 May 9;13(1):72. doi: 10.1038/s41408-023-00797-8. Blood Cancer J. 2023. PMID: 37156782 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
